Pharmacology of carvedilol

被引:87
作者
Dulin, B
Abraham, WT
机构
[1] Ohio State Univ, Ctr Heart, Div Cardiovasc Med, Columbus, OH 43210 USA
[2] Davis Heart & Lung Res Inst, Columbus, OH USA
关键词
D O I
10.1016/j.amjcard.2004.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carvedilol is a third-generation, neurohormonal antagonist with multiple activities. It blocks both beta(1)- and beta(2)-adrenergic receptors, enhances vasodilation via alpha(1)-adrenergic blockade, and, at high concentrations, has ion channel- blocking activities. Carvedilol locks sympathomimetic. activity. In addition to these well-known properties, carvedilol has a number of ancillary activities, including antioxidant, anti-inflammatory, and antiapoptotic properties. Together, they contribute to the clinical efficacy of carvedilol in a broad spectrum of patient types and may also confer a range of cardioprotective benefits. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:3B / 6B
页数:4
相关论文
共 27 条
[1]  
Abraham WT, 1998, CIRCULATION, V98, P378
[2]  
BRISTOW MR, 1992, CLIN INVESTIGATOR, V70, pS105
[3]   Mechanism of action of beta-blocking agents in heart failure [J].
Bristow, MR .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (11A) :L26-L40
[4]   SB211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits [J].
Brunvand, H ;
Liu, GL ;
Ma, XL ;
Yue, TL ;
Ruffolo, RR ;
Feuerstein, GZ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) :193-198
[5]  
CUBEDDU L X, 1987, Journal of Cardiovascular Pharmacology, V10, pS81, DOI 10.1097/00005344-198706111-00014
[6]   Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390
[7]   Effects of carvedilol on LV function and remodeling in patients with dilated cardiomyopathy with persistent LV dysfunction despite optimal conventional therapy [J].
Di Lenarda, A ;
Salvatore, L ;
Gregori, D ;
Sinagra, G ;
Sabbadini, G ;
Longaro, F ;
Bernobich, E ;
Klugmann, S ;
Camerini, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :189A-189A
[8]   Carvedilol - A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders [J].
Dunn, CJ ;
Lea, AP ;
Wagstaff, AJ .
DRUGS, 1997, 54 (01) :161-185
[9]   Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol [J].
Feuerstein, G ;
Yue, TL ;
Ma, XL ;
Ruffolo, RR .
PROGRESS IN CARDIOVASCULAR DISEASES, 1998, 41 (01) :17-24
[10]   CARVEDILOL, A NOVEL MULTIPLE ACTION ANTIHYPERTENSIVE AGENT WITH ANTIOXIDANT ACTIVITY AND THE POTENTIAL FOR MYOCARDIAL AND VASCULAR PROTECTION [J].
FEUERSTEIN, GZ ;
RUFFOLO, RR .
EUROPEAN HEART JOURNAL, 1995, 16 :38-42